AAAAAA
Results: 1-25/30
Authors:
Lovlie, R
Daly, AK
Matre, GE
Molven, A
Steen, VM
Citation: R. Lovlie et al., Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D635 allele in ultrarapid metabolism?, PHARMACOGEN, 11(1), 2001, pp. 45-55
Authors:
Daly, AK
Day, CP
Citation: Ak. Daly et Cp. Day, Candidate gene case-control association studies: advantages and potential pitfalls, BR J CL PH, 52(5), 2001, pp. 489-499
Authors:
Aithal, GP
Craggs, A
Day, CP
Welfare, M
Daly, AK
Mansfield, JC
Hudson, M
Citation: Gp. Aithal et al., Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease, DIG DIS SCI, 46(7), 2001, pp. 1520-1525
Authors:
Harbottle, A
Daly, AK
Atherton, K
Campbell, FC
Citation: A. Harbottle et al., Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance, INT J CANC, 92(6), 2001, pp. 777-783
Authors:
Brown, MA
Edwards, S
Hoyle, E
Campbell, S
Laval, S
Daly, AK
Pile, KD
Calin, A
Ebringer, A
Weeks, DE
Wordsworth, BP
Citation: Ma. Brown et al., Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis, HUM MOL GEN, 9(11), 2000, pp. 1563-1566
Authors:
Aithal, GP
Day, CP
Leathart, JBS
Daly, AK
Citation: Gp. Aithal et al., Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis, PHARMACOGEN, 10(6), 2000, pp. 511-518
Authors:
Smart, J
Daly, AK
Citation: J. Smart et Ak. Daly, Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms, PHARMACOGEN, 10(1), 2000, pp. 11-24
Authors:
Ingelman-Sundberg, M
Daly, AK
Oscarson, M
Nebert, DW
Citation: M. Ingelman-sundberg et al., Human cytochrome P450 (CYP) genes: recommendations for the nomenclature ofalleles, PHARMACOGEN, 10(1), 2000, pp. 91-93
Authors:
Ford, GA
Wood, SM
Daly, AK
Citation: Ga. Ford et al., CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system, BR J CL PH, 50(1), 2000, pp. 77-80
Authors:
Welfare, MR
Bassendine, MF
Daly, AK
Citation: Mr. Welfare et al., The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects, BR J CL PH, 49(3), 2000, pp. 240-243
Authors:
London, SJ
Smart, J
Daly, AK
Citation: Sj. London et al., Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County, LUNG CANC, 28(2), 2000, pp. 147-155
Authors:
Agarwal, K
Jones, DEJ
Daly, AK
James, OFW
Vaidya, B
Pearce, S
Bassendine, MF
Citation: K. Agarwal et al., CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis, J HEPATOL, 32(4), 2000, pp. 538-541
Authors:
Grove, J
Daly, AK
Bassendine, MF
Gilvarry, E
Day, CP
Citation: J. Grove et al., Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease, GUT, 46(4), 2000, pp. 540-545
Authors:
McSorley, LC
Daly, AK
Citation: Lc. Mcsorley et Ak. Daly, Identification of human cytochrome P450 isoforms that contribute to all-trans-Retinoic Acid 4-hydroxylation, BIOCH PHARM, 60(4), 2000, pp. 517-526
Authors:
Daly, AK
Grove, J
Citation: Ak. Daly et J. Grove, Pharmacogenomics, DRUG PHARM, 101, 2000, pp. 591-603
Authors:
Welfare, M
Adeokun, AM
Bassendine, MF
Daly, AK
Citation: M. Welfare et al., Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer, CANC EPID B, 8(4), 1999, pp. 289-292
Authors:
Welfare, MR
Aitkin, M
Bassendine, MF
Daly, AK
Citation: Mr. Welfare et al., Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians (vol 9, pg 367, 1999), PHARMACOGEN, 9(6), 1999, pp. 782-782
Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method
Authors:
Chen, GF
Tang, YM
Green, B
Lin, DX
Guengerich, FP
Daly, AK
Caporaso, NE
Kadlubar, FF
Citation: Gf. Chen et al., Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method, PHARMACOGEN, 9(3), 1999, pp. 327-332
Authors:
Welfare, MR
Aitkin, M
Bassendine, MF
Daly, AK
Citation: Mr. Welfare et al., Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians, PHARMACOGEN, 9(3), 1999, pp. 367-375
Authors:
Atkinson, A
Singleton, AB
Steward, A
Ince, PG
Perry, RH
McKeith, IG
Fairbairn, AF
Edwardson, JA
Daly, AK
Morris, CM
Citation: A. Atkinson et al., CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease, PHARMACOGEN, 9(1), 1999, pp. 31-35
Authors:
Nebert, DW
Ingelman-Sundberg, M
Daly, AK
Citation: Dw. Nebert et al., Genetic epidemiology of environmental toxicity and cancer susceptibility: Human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues, DRUG METAB, 31(2), 1999, pp. 467-487
Authors:
Jones, DEJ
Watt, FE
Grove, J
Newton, JL
Daly, AK
Gregory, WL
Day, CP
James, OFW
Bassendine, MF
Citation: Dej. Jones et al., Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis, J HEPATOL, 30(2), 1999, pp. 232-236
Authors:
Aithal, GP
Day, CP
Kesteven, PJL
Daly, AK
Citation: Gp. Aithal et al., Warfarin dose requirement and CYP2C9 polymorphisms - Reply, LANCET, 353(9168), 1999, pp. 1972-1973
Authors:
London, SJ
Idle, JR
Daly, AK
Coetzee, GA
Citation: Sj. London et al., Genetic variation of CYP2A6, smoking, and risk of cancer, LANCET, 353(9156), 1999, pp. 898-899
Authors:
Aithal, GP
Day, CP
Kesteven, PJL
Daly, AK
Citation: Gp. Aithal et al., Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, LANCET, 353(9154), 1999, pp. 717-719